Gokhale S
ORCID: 0000-0003-0554-099X
· 1 paper in corpus
2021
The BTK inhibitors ibrutinib and acalabrutinib are FDA-approved drugs for the treatment of B cell malignances. Both drugs have demonstrated clinical efficacy and safety profiles superior to chemoimmunotherapy regimens in patients with chron…